Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products.
Rebound is a full thickness placental-derived allograft matrix product. The company highlights that Rebound’s addition strengthens Celularity’s ability to serve a broader patient population in wound care and soft tissue repair.
“Rebound adds to our portfolio of placental-derived advanced biomaterial products, sales of which through the first half of 2024 were in excess of $24 million, which is greater than our full year sales in 2023,” said Robert J. Hariri, M.D., Ph.D., chairman, CEO, and founder of Celularity.
“We expect Rebound sales to contribute meaningfully in the fourth quarter 2024 and to fulfill expected full year 2024 biomaterial sales which we announced in February, augmenting our other revenues from biobanking and research agreements,” added Dr. Hariri. “I am very pleased with Celularity’s commercial traction and optimistic about our future performance.”
